Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd

Total Valuation

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd carries a market capitalization of 2.61B, placing it among publicly traded companies globally. Its enterprise value stands at 3.64B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd currently has 384.55M shares outstanding.

Valuation Ratios

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd trades at a trailing price-to-earnings ratio of 201.29. The price-to-sales ratio is 14.92, and the price-to-book ratio stands at 8.98.

Enterprise Valuation

On an enterprise value basis, Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd trades at an EV/EBITDA multiple of 89.74 and an EV/FCF ratio of 283.97. The EV/Sales ratio of 13.87 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 89.74 provides insight into valuation relative to core operating earnings.

Financial Position

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd maintains a current ratio of 2.36, meaning it holds 2.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.47, indicating elevated leverage, while an interest coverage ratio of 507.70 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd has paid 1.95M in income taxes, reflecting an effective tax rate of 9.11.

Stock Price Statistics

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd's stock has declined approximately -7.6087% over the past 52 weeks. The 50-day moving average sits at 7.64, while the 200-day moving average is 9.18.

Income Statement

Over the trailing twelve months, Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd generated 262.07M in revenue and converted that into 19.42M in net income, yielding earnings per share of 0.05. EBITDA reached 40.51M, while operating income came in at 40.51M.

Balance Sheet

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd holds 293.47M in cash and equivalents against 20.00M in total debt, resulting in a net debt position of -41.39M. Total book value stands at 435.41M, with working capital of 320.83M providing operational flexibility.

Cash Flow

After subtracting -12.73M in capital expenditures, free cash flow totaled -12.73M - equivalent to -0.03 per share.

Margins

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd operates with a gross margin of 42.84, reflecting its pricing power and cost economics. The operating margin of 15.46 and net profit margin of 7.41 provide insight into operational efficiency.

Dividends & Yields

The company's payout ratio of 0.41 indicates the proportion of earnings distributed to shareholders.

Stock Splits

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd's most recent stock split took place on January 23, 2008 with a 6250:6887 split ratio.

Scores

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd posts an Altman Z-Score of 9.06, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.